Drugs / Metabolically Armed CD19 CAR-T cells
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06711146 | Dec 2024 → Dec 2026 expected | systemic lupus erythematosus | Zhejiang University | Recruiting | No outcome recorded |
| Phase 0 | NCT06716164 | Dec 2024 → Dec 2026 expected | B-cell non-Hodgkin lymphoma | Zhejiang University | Recruiting | No outcome recorded |
| Phase 0 | NCT06393335 | May 2024 → Mar 2026 | acute lymphoblastic leukemia | The Children's Hospital of Zhejiang University School of Medicine | Unknown | No outcome recorded |
| Phase 0 | NCT06120166 | Nov 2023 → Dec 2025 overdue | diffuse large B-cell lymphoma | He Huang | Recruiting | No outcome recorded |
| Phase 0 | NCT06277011 | Feb 2023 → Feb 2025 | acute lymphoblastic leukemia | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05715606 | Feb 2023 → Feb 2025 | diffuse large B-cell lymphoma | Anhui Provincial Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metabolically Armed CD19 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06120166 ↗ |
| Modality | Cell therapy | “metabolically armed CD19 CAR-T Cells” NCT05715606 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT05715606 ↗ |
| Target | CD19 | “CD19 CAR-T cells” NCT05715606 ↗ |